Drug Interaction Dilemmas

Abstract

Available from <frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 110_cong_ public_laws&docid=f:publ085.110>. 3. Leiderman DB. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend 2009; 105 (suppl 1): S9-S13. 4. US Food and Drug Administration. Guidance for industry. Format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications. Silver Spring: US Food and Drug Administration; 2009. Available from <www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/UCM184128.pdf>. 5. American Pharmacists Association. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system. J Am Pharm Assoc (2003) 2009; 49: 729-43. 6. US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Silver Spring: US Food and Drug Administration; 2010. Available from <www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm111350.htm>. 7. US Food and Drug Administration. Identification of drug and biological products deemed to have Risk Evaluation and Mitigation Strategies for purposes of the Food and Drug Administration Act of 2007.